{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:34:23Z","timestamp":1794368063491,"version":"4.9.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dengue is the most common viral infection spread by mosquitoes, prevalent in tropical countries. The acute dengue virus (DENV) infection is a benign and primarily febrile illness. However, secondary infection with alternative serotypes can worsen the condition, leading to severe and potentially fatal dengue. The antibody raised by the vaccine or the primary infections are frequently cross-reactive; however, weakly neutralizing, and during subsequent infection, they may increase the odds of antibody-dependent enhancement (ADE). Despite that, many neutralizing antibodies have been identified against the DENV, which are thought to be useful in reducing dengue severity. Indeed, an antibody must be free from ADE for therapeutic application, as it is pretty common in dengue infection and escalates disease severity. Therefore, this review has described the critical characteristics of DENV and the potential immune targets in general. The primary emphasis is given to the envelope protein of DENV, where potential epitopes targeted for generating serotype-specific and cross-reactive antibodies have critically been described. In addition, a novel class of highly neutralizing antibodies targeted to the quaternary structure, similar to viral particles, has also been described. Lastly, we have discussed different aspects of the pathogenesis and ADE, which would provide significant insights into developing safe and effective antibody therapeutics and equivalent protein subunit vaccines.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1200195","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:04:45Z","timestamp":1685693085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":100,"title":["Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement"],"prefix":"10.3389","volume":"14","author":[{"given":"Animesh","family":"Sarker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinkoo Devi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev.micro.62.081307.163005","article-title":"Global spread and persistence of dengue","volume":"62","author":"Kyle","year":"2008","journal-title":"Annu Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/jtm\/taab146","article-title":"Global burden for dengue and the evolving pattern in the past 30 years","volume":"28","author":"Yang","year":"2021","journal-title":"J Trop Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/tra.12012","article-title":"Molecular mechanisms involved in antibody- dependent enhancement of dengue virus infection in humans","volume":"14","author":"Flipse","year":"2013","journal-title":"Traffic (Copenhagen Denmark)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-3527(08)00401-6","article-title":"The history and evolution of human dengue emergence","volume":"72","author":"Vasilakis","year":"2008","journal-title":"Adv Virus Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-020-04653-z","article-title":"Molecular and evolutionary analysis of dengue virus serotype 2 isolates from Korean travelers in 2015","volume":"165","author":"Hwang","year":"2020","journal-title":"Arch Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.022","article-title":"The pathogenesis of dengue","volume":"29","author":"Whitehorn","year":"2011","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2007.0050","article-title":"Antibody to dengue 1 detected more than 60 years after infection","volume":"20","author":"Imrie","year":"2007","journal-title":"Viral Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.80820","article-title":"Current status of vaccines against dengue virus","volume":"64","author":"Casta\u00f1o-Osorio","year":"2018","journal-title":"Dengue Fever - Resilient Threat Face Innovation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.839941","article-title":"Therapeutic antibodies as a treatment option for dengue fever","volume":"11","author":"Chan","year":"2013","journal-title":"Exp Rev Anti-infect Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00157","article-title":"Anti-idiotypic antibodies specific to prM monoantibody prevent antibody dependent enhancement of dengue virus infection","volume":"7","author":"Wang","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/biology10090941","article-title":"Modeling dengue immune responses mediated by antibodies: a qualitative study","volume":"10","author":"Sebayang","year":"2021","journal-title":"Biol (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1983.32.154","article-title":"Original antigenic sin in dengue","volume":"32","author":"Halstead","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01826-10","article-title":"An in-depth analysis of original antigenic sin in dengue virus infection","volume":"85","author":"Midgley","year":"2011","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(09)70290-2","article-title":"Immunogenicity of sanofi pasteur tetravalent dengue vaccine","volume":"46","author":"Guy","year":"2009","journal-title":"J Clin Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.11.019","article-title":"Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs","volume":"95","author":"Dans","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70254-3","article-title":"Progress towards a dengue vaccine","volume":"9","author":"Webster","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the sanofi-pasteur CYD\u2122 vaccine? expert rev","volume":"15","author":"Whitehead","year":"2016","journal-title":"Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"Randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.15406\/moji.2017.05.00145","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2016","volume":"6","author":"Cai","year":"2017","journal-title":"MOJI"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1227901","article-title":"Techno-economic analysis of a transient plant-based platform for monoclonal antibody production","volume":"8","author":"Nandi","year":"2016","journal-title":"mAbs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.10.012","article-title":"Antibody with an engineered fc region as a therapeutic agent against dengue virus infection","volume":"124","author":"Ramadhany","year":"2015","journal-title":"Antiviral Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21775\/9781910190159","article-title":"Molecular virology and control of flaviviruses","author":"Shi","year":"2012","journal-title":"Caister Acad press"},{"key":"B27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat Microbiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/rmv.712","article-title":"Neuroinvasive flavivirus infections","volume":"22","author":"Sips","year":"2012","journal-title":"Rev Med Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/v9050097","article-title":"Historical perspectives on flavivirus research","volume":"9","author":"Holbrook","year":"2017","journal-title":"Viruses"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf5316","article-title":"The 3.8 a resolution cryo-EM structure of zika virus","volume":"52","author":"Sirohi","year":"2016","journal-title":"Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/v6010069","article-title":"Flavivirus entry receptors:an update","volume":"6","author":"Perera-Lecoin","year":"2013","journal-title":"Viruses"},{"key":"B32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/ijms19010054","article-title":"Development of antibody therapeutics against flavivirus","volume":"19","author":"Sun","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/elw040","article-title":"Genomics, proteomics and evolution of dengue virus","volume":"16","author":"Dwivedi","year":"2017","journal-title":"Brief Funct Genom"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PloS Negl Trop Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003084","article-title":"Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity","volume":"3","author":"OhAinle","year":"2011","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7352","article-title":"Widespread intra-serotype recombination in natural populations of dengue virus","volume":"96","author":"Worobey","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83122-0","article-title":"Multiple recombinant dengue type 1 viruses in an isolate from a dengue patient","volume":"88","author":"Aaskov","year":"2007","journal-title":"J Gen Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(99)01669-8","article-title":"The causes and consequences of genetic variation in dengue virus","volume":"8","author":"Holmes","year":"2000","journal-title":"Trends Microbiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1567-1348(03)00004-2","article-title":"The origin, emergence and evolutionary genetics of dengue virus","volume":"3","author":"Holmes","year":"2003","journal-title":"Infection Genet Evolution: J Mol Epidemiol Evolutionary Genet Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008049","article-title":"Genomic epidemiological characteristics of dengue fever in guangdong province, China from 2013 to 2017","volume":"14","author":"Sun","year":"2020","journal-title":"PloS Neg Trop Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3390\/tropicalmed7080180","article-title":"Dengue incidence trends and its burden in major endemic regions from 1990 to 2019","volume":"7","author":"Tian","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular insight into dengue virus pathogenesis and its implications for disease control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02411-14","article-title":"Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers","volume":"89","author":"Zhang","year":"2014","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","article-title":"Structure of dengue virus: implications for flavivirus organization, maturation, and fusion","volume":"108","author":"Kuhn","year":"2002","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01874-13","article-title":"A mouse monoclonal antibody against dengue virus type 1 mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity","volume":"87","author":"Yamanaka","year":"2013","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microb"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2463","article-title":"Cryo-EM structure of the mature dengue virus at 3.5-\u00c5 resolution","volume":"20","author":"Zhang","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.439","article-title":"Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus","volume":"31","author":"Cockburn","year":"2011","journal-title":"EMBO J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01190-10","article-title":"Genotype-specific neutralization and protection by antibodies against dengue virus type 3","volume":"84","author":"Brien","year":"2010","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01087-10","article-title":"Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2","volume":"84","author":"Sukupolvi-Petty","year":"2010","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1371\/journal.pone.0004991","article-title":"Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens","volume":"4","author":"Crill","year":"2009","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12985-017-0856-8","article-title":"Characterization and epitope mapping of dengue virus type 1 specific monoclonal antibodies","volume":"14","author":"Chen","year":"2017","journal-title":"Virol J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004072","article-title":"Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement","volume":"10","author":"Edeling","year":"2014","journal-title":"PloS Pathog"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002930","article-title":"Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope","volume":"8","author":"Austin","year":"2012","journal-title":"PloS Pathog"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1000823","DOI":"10.1371\/journal.ppat.1000823","article-title":"The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1","volume":"6","author":"Shrestha","year":"2010","journal-title":"PloS Pathog"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00432-07","article-title":"Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes","volume":"81","author":"Sukupolvi-Petty","year":"2007","journal-title":"J Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006934","article-title":"Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes","volume":"14","author":"Gallichotte","year":"2018","journal-title":"PloS Pathog"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.01.001","article-title":"Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody","volume":"20","author":"Cockburn","year":"2012","journal-title":"Structure"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139741","article-title":"Characterization of a novel dengue serotype 4 virus-specific neutralizing epitope on the envelope protein domain III","volume":"10","author":"Ji","year":"2015","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0227-7","article-title":"Characterization of a potent and highly unusual minimally-enhancing antibody directed against dengue virus","volume":"19","author":"Renner","year":"2018","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200227","article-title":"Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity","volume":"188","author":"Midgley","year":"2012","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05237-11","article-title":"A fusion-loop antibody enhances the infectious properties of immature flavivirus particles","volume":"85","author":"Rodenhuis-Zybert","year":"2011","journal-title":"J Virol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007836","article-title":"A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III","volume":"15","author":"Hu","year":"2019","journal-title":"PloS Pathog"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2017.11.017","article-title":"Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope","volume":"26","author":"Li","year":"2018","journal-title":"Structure"},{"key":"B67","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2015.06.057","article-title":"Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006209","article-title":"Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue e protein","volume":"12","author":"Budigi","year":"2018","journal-title":"PloS Neg Trop Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1099\/vir.0.006874-0","article-title":"On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes","volume":"90","author":"Rajamanonmani","year":"2009","journal-title":"J Gen Virol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4021","article-title":"Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity","volume":"5","author":"Injampa","year":"2017","journal-title":"PeerJ"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-016-0003-3","article-title":"A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus","volume":"2","author":"Xu","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B72","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","article-title":"Structures of the zika virus envelope protein and its complex with a flavivirus broadly protective antibody","volume":"19","author":"Dai","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016059","article-title":"A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of e protein","volume":"6","author":"Deng","year":"2011","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"mBio"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007716","article-title":"Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes","volume":"15","author":"Li","year":"2019","journal-title":"PloS Pathog"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38970","article-title":"Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody","volume":"7","author":"Shen","year":"2020","journal-title":"eLife"},{"key":"B77","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent potent human neutralizing antibodies to zika virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0746-2","article-title":"Potent zika and dengue cross-neutralizing antibodies induced by zika vaccination in a dengue-experienced donor","volume":"26","author":"Dussupt","year":"2020","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00406-17","article-title":"Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype fab complex","volume":"91","author":"Wong","year":"2017","journal-title":"J Virol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7341","article-title":"A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins","volume":"6","author":"Fibriansah","year":"2015","journal-title":"Nat Comm"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of e protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01461-15","article-title":"A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies","volume":"6","author":"Gallichotte","year":"2015","journal-title":"mBio"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52384.sa2","article-title":"Broadly neutralizing human antibodies against dengue virus identified by single b cell transcriptomics","volume":"8","author":"Durham","year":"2019","journal-title":"elife"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01559-15","article-title":"Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing","volume":"6","author":"Dowd","year":"2015","journal-title":"mBio"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83028-0","article-title":"Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus","volume":"88","author":"Lisova","year":"2007","journal-title":"J Gen Virol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00170-10","article-title":"In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein","volume":"84","author":"Liao","year":"2010","journal-title":"J Virol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","article-title":"The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry","volume":"9","author":"Chin","year":"2007","journal-title":"Microbes Infect"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(87)90056-8","article-title":"Profiles of antibody-dependent enhancement of dengue virus type 2 infection","volume":"3","author":"Morens","year":"1987","journal-title":"Microb Pathog"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.007","article-title":"Identification of dengue virus serotype 3 specific antigenic sites targeted by neutralizing human antibodies","volume":"27","author":"Young","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.06.057","article-title":"Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection","volume":"423","author":"Setthapramote","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003157","article-title":"Therapeutic efficacy of antibodies lacking fc\u03b3 receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies","volume":"9","author":"Williams","year":"2013","journal-title":"PloS Pathog"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.245","article-title":"Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody","volume":"28","author":"Cherrier","year":"2009","journal-title":"EMBO J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209576","article-title":"Designing antibody against highly conserved region of dengue envelope protein by in silico screening of scFv mutant library","volume":"14","author":"Rathore","year":"2019","journal-title":"PloS One"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-10541-y","article-title":"Production and immunogenicity of fubc subunit protein redesigned from DENV envelope protein","volume":"104","author":"Rathore","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"101772","DOI":"10.1016\/j.jbc.2022.101772","article-title":"Structure-guided affinity maturation of a single-chain variable fragment antibody against the fu-bc epitope of the dengue virus envelope protein","volume":"298","author":"Sarker","year":"2022","journal-title":"J Biol Chem"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1008103","DOI":"10.1371\/journal.ppat.1008103","article-title":"Broad dengue neutralization in mosquitoes expressing an engineered antibody","volume":"16","author":"Buchman","year":"2020","journal-title":"PloS Pathog"},{"key":"B100","doi-asserted-by":"publisher","first-page":"324780","DOI":"10.1101\/2020.10.03.324780","article-title":"A potent neutralizing mouse monoclonal antibody specific to dengue virus type 1 mochizuki strain recognized a novel epitope around the n-67 glycan on the e protein: a possible explanation of dengue virus evolution regarding the acquisition of n-67 glycan","volume":"10","author":"Kotaki","year":"2020","journal-title":"bioRxiv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.055178-0","article-title":"Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design","volume":"94","author":"Li","year":"2013","journal-title":"J Gen Virol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1382","article-title":"Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins","volume":"15","author":"Lok","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01023-18","article-title":"Engineered dengue virus domain III proteins elicit cross-neutralizing antibody responses in mice","volume":"92","author":"Frei","year":"2018","journal-title":"J Virol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303645110","article-title":"Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency","volume":"110","author":"Tharakaraman","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.05.007","article-title":"Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates","volume":"144","author":"Ong","year":"2017","journal-title":"Antiviral Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3849","article-title":"Human antibodies to the dengue virus e-dimer epitope have therapeutic activity against zika virus infection","volume":"18","author":"Fernandez","year":"2017","journal-title":"Nat Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"Dengue virus: cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking e protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"B108","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci Trans Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody- mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2174\/156652409787581592","article-title":"Dengue: recent advances in biology and current status of translational research","volume":"9","author":"Swaminathan","year":"2009","journal-title":"Curr Mol Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3539","article-title":"Immunogenic cross-talk between dengue and zika viruses","volume":"17","author":"Harrison","year":"2016","journal-title":"Nat Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82537-0","article-title":"Dengue virus (DENV) antibody- dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells","volume":"88","author":"Chareonsirisuthigul","year":"2007","journal-title":"J Gen Virol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01805-15","article-title":"Dengue virus prM-specific human monoclonal antibodies with virus replication-enhancing properties recognize a single immunodominant antigenic site","volume":"90","author":"Smith","year":"2016","journal-title":"J Virol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.12932\/AP0728","article-title":"Strategies to improve the immunogenicity of prM+E dengue virus type-2 DNA vaccine","volume":"35","author":"Ketloy","year":"2017","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.5.2754","article-title":"Partial agonist effect influences the CTL response to a heterologous dengue virus serotype","volume":"163","author":"Zivny","year":"1999","journal-title":"GSBS Student Publications"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1993.48.324","article-title":"Serum levels of tumor necrosis factor-alpha (TNF- alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients","volume":"48","author":"Hober","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"B118","doi-asserted-by":"publisher","first-page":"9713","DOI":"10.1097\/MD.0000000000009713","article-title":"Identifying protein biomarkers in predicting disease severity of dengue virus infection using immune-related protein microarray","volume":"97","author":"Soe","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.178061","article-title":"Therapeutic antibodies for infectious diseases","volume":"95","author":"Sparrow","year":"2017","journal-title":"Bull World Health Organ"},{"key":"B121","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"mAbs"},{"key":"B122","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"6","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.01.004","article-title":"Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease","volume":"7","author":"Zellweger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2174\/0929866525666180925142757","article-title":"Recent developments toward antibody engineering and affinity maturation","volume":"25","author":"Rathore","year":"2018","journal-title":"Protein Pept Lett"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human fc\u03b3 receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo b-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00327-13","article-title":"Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus","volume":"87","author":"Brien","year":"2013","journal-title":"J Virol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1148850","article-title":"A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion","volume":"8","author":"Shi","year":"2016","journal-title":"mAbs"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/372379a0","article-title":"Crystal structure of the complex of rat neonatal fc receptor with fc","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607161200","article-title":"Monoclonal antibody clearance impact of modulating the interaction of IgG with the neonatal fc receptor","volume":"282","author":"Datta-Mannan","year":"2007","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.346","article-title":"An engineered human IgG1 antibody with longer serum half-life","volume":"176","author":"Hinton","year":"2006","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-065X.2008.00601.x","article-title":"Engineering therapeutic monoclonal antibodies","volume":"22","author":"Liu","year":"2008","journal-title":"Immunol Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"\u201cGerminal centers.\u201d","volume":"30","author":"Victora","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13073-016-0276-1","article-title":"Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent b cell response","volume":"8","author":"Godoy-Lozano","year":"2016","journal-title":"Genome Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:04:49Z","timestamp":1685693089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2023.1200195"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1200195","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1200195"}}